Parisa Naeem
Anticarcinogenic impact of extracellular vesicles (exosomes) from cord blood stem cells in malignant melanoma: A potential biological treatment
Naeem, Parisa; Baumgartner, Adi; Ghaderi, Nader; Sefat, Farshid; Alhawamdeh, Maysa; Heidari, Saeed; Shahzad, Fanila; Swaminathan, Karthic; Akhbari, Pouria; Isreb, Mohammad; Anderson, Diana; Wright, Andrew; Najafzadeh, Mojgan
Authors
Adi Baumgartner
Nader Ghaderi
Farshid Sefat
Maysa Alhawamdeh
Saeed Heidari
Fanila Shahzad fanila.shahzad@durham.ac.uk
PGR Student Doctor of Philosophy
Karthic Swaminathan
Pouria Akhbari
Mohammad Isreb
Diana Anderson
Andrew Wright
Mojgan Najafzadeh
Abstract
Incidence of Malignant Melanoma has become the 5th in the UK. To date, the major anticancer therapeutics include cell therapy, immunotherapy, gene therapy and nanotechnology-based strategies. Recently, extracellular vesicles, especially exosomes, have been highlighted for their therapeutic benefits in numerous chronic diseases. Exosomes display multifunctional properties, including inhibition of cancer cell proliferation and initiation of apoptosis. In the present in vitro study, the antitumour effect of cord blood stem cell (CBSC)-derived exosomes was confirmed by the CCK-8 assay (p < 0.05) on CHL-1 melanoma cells and improve the repair mechanism on lymphocytes from melanoma patients. Importantly, no significant effect was observed in healthy lymphocytes when treated with the exosome concentrations at 24, 48 and 72 h. Comet assay results (OTM and %Tail DNA) demonstrated that the optimal exosome concentration showed a significant impact (p < 0.05) in lymphocytes from melanoma patients whilst causing no significant DNA damage in lymphocytes of healthy volunteers was 300 μg/ml. Similarly, the Comet assay results depicted significant DNA damage in a melanoma cell line (CHL-1 cells) treated with CBSC-derived exosomes, both the cytotoxicity of CHL-1 cells treated with CBSC-derived exosomes exhibited a significant time-dependent decrease in cell survival. Sequencing analysis of CBSC exosomes showed the presence of the let-7 family of miRNAs, including let-7a-5p, let-7b-5p, let-7c-5p, let-7d-3p, let-7d-5p and two novel miRNAs. The potency of CBSC exosomes in inhibiting cancer progression in lymphocytes from melanoma patients and CHL-1 cells whilst causing no harm to the healthy lymphocytes makes it a potential candidate as an anticancer therapy.
Citation
Naeem, P., Baumgartner, A., Ghaderi, N., Sefat, F., Alhawamdeh, M., Heidari, S., …Najafzadeh, M. (2023). Anticarcinogenic impact of extracellular vesicles (exosomes) from cord blood stem cells in malignant melanoma: A potential biological treatment. Journal of Cellular and Molecular Medicine, 27(2), https://doi.org/10.1111/jcmm.17639
Journal Article Type | Article |
---|---|
Acceptance Date | Oct 28, 2022 |
Online Publication Date | Dec 22, 2022 |
Publication Date | 2023 |
Deposit Date | Mar 27, 2023 |
Publicly Available Date | Mar 27, 2023 |
Journal | Journal of Cellular and Molecular Medicine |
Print ISSN | 1582-1838 |
Electronic ISSN | 1582-4934 |
Publisher | Wiley Open Access |
Peer Reviewed | Peer Reviewed |
Volume | 27 |
Issue | 2 |
DOI | https://doi.org/10.1111/jcmm.17639 |
Public URL | https://durham-repository.worktribe.com/output/1178356 |
Files
Published Journal Article
(1.3 Mb)
PDF
Publisher Licence URL
http://creativecommons.org/licenses/by/4.0/
Copyright Statement
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Downloadable Citations
About Durham Research Online (DRO)
Administrator e-mail: dro.admin@durham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search